Re‐irradiation in patients with progressive or recurrent brain metastases from extracranial solid tumors: A novel prognostic index

Background Most studies evaluating factors associated with the survival of patients with brain metastases (BM) have focused on patients with newly diagnosed BM. This study aimed to identify prognostic factors associated with survival after brain re‐irradiation in order to develop a new prognostic in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer medicine (Malden, MA) MA), 2023-01, Vol.12 (1), p.146-158
Hauptverfasser: Gutierrez Torres, Salvador, Maldonado Magos, Federico, Turcott, Jenny G., Hernandez‐Martinez, Juan‐Manuel, Cacho‐Díaz, Bernardo, Cardona, Andrés F., Mota‐García, Aida, Lozano Ruiz, Francisco, Ramos‐Ramirez, Maritza, Arrieta, Oscar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Most studies evaluating factors associated with the survival of patients with brain metastases (BM) have focused on patients with newly diagnosed BM. This study aimed to identify prognostic factors associated with survival after brain re‐irradiation in order to develop a new prognostic index. Methods This 5‐year retrospective study included patients treated with repeat‐radiotherapy for recurrent BM at the “Instituto Nacional de Cancerología” of Mexico between 2015 and 2019. Significant variables in the multivariate Cox regression analysis were used to create the brain re‐irradiation index (BRI). Survival and group comparisons were performed using the Kaplan–Meier method and the log‐rank test. Results Fifty‐seven patients receiving brain re‐irradiation were identified. Most patients were women (75.4%) with a mean age at BM diagnosis of 51.4 years. Lung and breast cancer were the most prevalent neoplasms (43.9% each). Independent prognostic factors for shorter survival after re‐irradiation were: Age >50 years (hazard ratio [HR]:2.5 [95% confidence interval [CI], 1.1–5.8]; p = 0.026), uncontrolled primary tumor (HR:5.5 [95% CI, 2.2–13.5]; p 20 mm (4.6 [95% CI, 1.7–12.2]; p = 0.002), and an interval
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4921